Page 6 - Single Agent News Today : Breaking News, Live Updates & Top Stories | Vimarsana

KEYNOTE-564 is the First Phase 3 Study to Show Positive Results for Adjuvant Immunotherapy in RCC First-Time Disease-Free Survival Data to be Presented During Plenary Session at the 2021 ASCO Annual Meeting Merck known as MSD outside the United States and Canada, today announced first-time results from the pivotal Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, for the potential adjuvant … KEYNOTE-564 is the First Phase 3 Study to Show Positive Results for Adjuvant Immunotherapy in RCC First-Time Disease-Free Survival Data to be Presented During Plenary Sessio...

119 Abstracts and Presentations Featuring Sarah Cannon's Clinical Research and Care Insights Today, Sarah Cannon announced it will present its latest cancer research insights at the American Society

In Pivotal Study, KEYTRUDA ® In Combination With Chemotherapy Before Surgery and Continuing as a Single Agent After Surgery Showed Statistically Significant Improvement in EFS Versus Pre-Operative Chemotherapy KEYTRUDA Is the First Anti-PD-1 Therapy to Show a Statistically Significant Improvement in EFS as Neoadjuvant and Adjuvant Therapy for TNBC Merck known as MSD outside the United States and Canada, today … In Pivotal Study, KEYTRUDA ® (pembrolizumab) In Combination With Chemotherapy Before Surgery and Continuing as a Single Agent After Surgery Showed Statistically Significant Imp...

Applications Based on Progression-Free Survival, Overall Survival, and Objective Response Rate Data From Respective Pivotal Phase 3 Trials Merck known as MSD outside the United States and Canada, and Eisai Inc. today announced that the U.S. Food and Drug Administration has accepted and granted priority review for applications seeking two new approvals for the combination of KEYTRUDA, Merck’s anti-PD-1 therapy, … Applications Based on Progression-Free Survival, Overall Survival, and Objective Response Rate Data From Respective Pivotal Phase 3 Trials Merck (NYSE: MRK), known as MSD outsi...

Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program First-Time Data for KEYTRUDA ® in Early-Stage Kidney Cancer and for LYNPARZA ® in Early-Stage Breast Cancer To Be Featured in ASCO Plenary Session New Data To Be Presented for KEYTRUDA in Advanced Gastric Cancer Merck known as MSD outside the United States and Canada, today announced that data spanning more than 20 cancer types from its oncology research program will be presented at the 2021 American Society of … First-Time Data for KEYTRUDA ® (olaparib) ...